Concepts (140)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 14 | 2018 | 409 | 1.500 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2018 | 101 | 1.100 |
Why?
|
| Quinazolines | 4 | 2013 | 38 | 0.880 |
Why?
|
| Neoplasms, Vascular Tissue | 1 | 2012 | 7 | 0.430 |
Why?
|
| Knee Prosthesis | 1 | 2012 | 15 | 0.430 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2012 | 23 | 0.420 |
Why?
|
| Antineoplastic Agents | 5 | 2018 | 607 | 0.410 |
Why?
|
| Sarcoma | 1 | 2012 | 71 | 0.400 |
Why?
|
| Osteoarthritis, Knee | 1 | 2012 | 90 | 0.400 |
Why?
|
| Periodicals as Topic | 1 | 2012 | 91 | 0.380 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2012 | 89 | 0.380 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2011 | 33 | 0.380 |
Why?
|
| Angiotensin I | 1 | 2012 | 240 | 0.360 |
Why?
|
| Carcinoma | 1 | 2011 | 92 | 0.360 |
Why?
|
| Peptide Fragments | 1 | 2012 | 398 | 0.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2018 | 461 | 0.290 |
Why?
|
| Aged | 14 | 2018 | 10288 | 0.230 |
Why?
|
| Adenocarcinoma | 3 | 2017 | 311 | 0.230 |
Why?
|
| Middle Aged | 15 | 2018 | 11824 | 0.230 |
Why?
|
| Radiosurgery | 4 | 2017 | 356 | 0.230 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2017 | 85 | 0.220 |
Why?
|
| Brain Neoplasms | 3 | 2017 | 638 | 0.220 |
Why?
|
| Gene Expression Profiling | 3 | 2017 | 323 | 0.210 |
Why?
|
| Cyclin D3 | 2 | 2013 | 4 | 0.210 |
Why?
|
| Cyclin D1 | 2 | 2013 | 14 | 0.210 |
Why?
|
| Humans | 21 | 2018 | 31836 | 0.210 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 319 | 0.200 |
Why?
|
| Aged, 80 and over | 8 | 2018 | 3988 | 0.200 |
Why?
|
| Retrospective Studies | 8 | 2018 | 3488 | 0.190 |
Why?
|
| Adult | 10 | 2018 | 9327 | 0.190 |
Why?
|
| Male | 15 | 2018 | 19091 | 0.180 |
Why?
|
| Treatment Outcome | 5 | 2017 | 3294 | 0.180 |
Why?
|
| Female | 15 | 2018 | 19859 | 0.180 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 194 | 0.170 |
Why?
|
| Carboplatin | 1 | 2018 | 48 | 0.160 |
Why?
|
| Paclitaxel | 1 | 2018 | 67 | 0.160 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 39 | 0.150 |
Why?
|
| Immunotherapy | 1 | 2018 | 80 | 0.150 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 23 | 0.140 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 55 | 0.140 |
Why?
|
| Fetal Proteins | 1 | 2016 | 7 | 0.140 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2016 | 10 | 0.140 |
Why?
|
| T-Box Domain Proteins | 1 | 2016 | 14 | 0.140 |
Why?
|
| Sulfides | 1 | 2016 | 27 | 0.140 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2016 | 17 | 0.140 |
Why?
|
| Caprylates | 1 | 2016 | 28 | 0.140 |
Why?
|
| Hospice Care | 1 | 2016 | 13 | 0.140 |
Why?
|
| Terminal Care | 1 | 2016 | 24 | 0.140 |
Why?
|
| Smoking | 2 | 2017 | 499 | 0.140 |
Why?
|
| Neoplasms | 3 | 2018 | 692 | 0.130 |
Why?
|
| Taxoids | 2 | 2013 | 59 | 0.130 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 272 | 0.130 |
Why?
|
| Palliative Care | 1 | 2016 | 52 | 0.130 |
Why?
|
| Cryopreservation | 1 | 2016 | 55 | 0.130 |
Why?
|
| Mice | 2 | 2012 | 2476 | 0.130 |
Why?
|
| Spermatogenesis | 1 | 2016 | 47 | 0.130 |
Why?
|
| Testis | 1 | 2016 | 62 | 0.130 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 221 | 0.130 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2015 | 10 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2016 | 369 | 0.120 |
Why?
|
| Lung | 1 | 2016 | 255 | 0.120 |
Why?
|
| Mutation | 1 | 2017 | 487 | 0.120 |
Why?
|
| Dapsone | 1 | 2014 | 4 | 0.120 |
Why?
|
| Mediastinal Neoplasms | 1 | 2014 | 13 | 0.120 |
Why?
|
| Anemia, Hemolytic | 1 | 2014 | 7 | 0.120 |
Why?
|
| Cell Proliferation | 2 | 2016 | 598 | 0.120 |
Why?
|
| Hydroxamic Acids | 1 | 2014 | 21 | 0.120 |
Why?
|
| Filgrastim | 1 | 2013 | 4 | 0.120 |
Why?
|
| Thorax | 1 | 2014 | 29 | 0.120 |
Why?
|
| Survival | 1 | 2013 | 13 | 0.120 |
Why?
|
| Radiotherapy, Conformal | 2 | 2012 | 19 | 0.120 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2013 | 24 | 0.110 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 156 | 0.110 |
Why?
|
| Carcinoma, Small Cell | 1 | 2013 | 25 | 0.110 |
Why?
|
| Polyethylene Glycols | 1 | 2013 | 64 | 0.110 |
Why?
|
| Cisplatin | 1 | 2013 | 77 | 0.110 |
Why?
|
| Salvage Therapy | 1 | 2014 | 134 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 180 | 0.110 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 247 | 0.110 |
Why?
|
| Cementation | 1 | 2012 | 1 | 0.110 |
Why?
|
| Esophagitis | 1 | 2012 | 5 | 0.110 |
Why?
|
| Pregnancy Proteins | 1 | 2012 | 13 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 2271 | 0.110 |
Why?
|
| Esophagus | 1 | 2012 | 22 | 0.110 |
Why?
|
| Prosthesis Design | 1 | 2012 | 95 | 0.100 |
Why?
|
| Glioblastoma | 1 | 2014 | 156 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2013 | 154 | 0.100 |
Why?
|
| Cyclin E | 1 | 2011 | 5 | 0.100 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2011 | 5 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2012 | 461 | 0.100 |
Why?
|
| NIH 3T3 Cells | 1 | 2011 | 43 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 353 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2011 | 104 | 0.090 |
Why?
|
| Animals | 2 | 2012 | 7450 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 531 | 0.090 |
Why?
|
| Astrocytoma | 1 | 2008 | 29 | 0.080 |
Why?
|
| Time Factors | 1 | 2012 | 2146 | 0.070 |
Why?
|
| Survival Rate | 3 | 2016 | 884 | 0.070 |
Why?
|
| Neoplasm Staging | 3 | 2014 | 456 | 0.070 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 725 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2018 | 1824 | 0.050 |
Why?
|
| Radiotherapy Dosage | 2 | 2014 | 101 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 564 | 0.050 |
Why?
|
| Prognosis | 2 | 2014 | 1498 | 0.040 |
Why?
|
| Genes, erbB-1 | 1 | 2017 | 15 | 0.040 |
Why?
|
| Clone Cells | 1 | 2017 | 36 | 0.040 |
Why?
|
| Genes, Neoplasm | 1 | 2017 | 18 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2017 | 23 | 0.040 |
Why?
|
| Genes, ras | 1 | 2017 | 25 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 135 | 0.040 |
Why?
|
| Topotecan | 1 | 2016 | 17 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 61 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 99 | 0.030 |
Why?
|
| Tissue Banks | 1 | 2016 | 15 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 756 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 148 | 0.030 |
Why?
|
| Infertility, Male | 1 | 2016 | 24 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 487 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 390 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 979 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2016 | 129 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 593 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 1187 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2015 | 81 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 89 | 0.030 |
Why?
|
| Radiography | 1 | 2015 | 376 | 0.030 |
Why?
|
| Hospitalization | 1 | 2016 | 463 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2016 | 687 | 0.030 |
Why?
|
| Tracheoesophageal Fistula | 1 | 2012 | 5 | 0.030 |
Why?
|
| Remission Induction | 1 | 2012 | 84 | 0.030 |
Why?
|
| Infant | 1 | 2016 | 1055 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2012 | 162 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 192 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2016 | 1259 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 61 | 0.020 |
Why?
|
| Child | 1 | 2016 | 2425 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2010 | 132 | 0.020 |
Why?
|
| Adolescent | 1 | 2016 | 3511 | 0.020 |
Why?
|
| United States | 1 | 2016 | 3925 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 297 | 0.020 |
Why?
|